Skip to main content

Targeted Anti-Cancer Therapies

Project description

Next-generation protein-drug conjugates for cancer therapy

Antibody-drug conjugates (ADCs) represent the fast-growing class of cancer therapeutics. They consist of a highly potent cytotoxic drug linked to an antibody that is specifically targeting certain tumour markers. By combining the cytotoxicity of the drug and the targeting properties of the antibody, ADCs selectively kill cancer cells. The EU-funded TACT project is an innovative, international, multidisciplinary training and research programme designed to train 11 early-stage researchers in the field of anti-cancer therapeutics, creating a new generation of experts. Specifically, the TACT research programme will focus on key principles of the development of a new and more potent generation of protein-drug conjugates employing site-specific bioconjugation methods, environment-specific cleavable linkers, more efficient protein-based targeting systems and new analytical tools for protein characterisation.

Call for proposal

H2020-MSCA-ITN-2019
See other projects for this call

Funding Scheme

MSCA-ITN-ETN - European Training Networks

Coordinator

UNIVERSITE DE STRASBOURG
Address
Rue Blaise Pascal 4
67081 Strasbourg
France
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 549 604,08

Participants (8)

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
France
EU contribution
€ 274 802,04
Address
Rue Michel Ange 3
75794 Paris
Activity type
Research Organisations
UNIVERSITY COLLEGE LONDON
United Kingdom
EU contribution
€ 303 172,56
Address
Gower Street
WC1E 6BT London
Activity type
Higher or Secondary Education Establishments
THE QUEEN'S UNIVERSITY OF BELFAST
United Kingdom
EU contribution
€ 606 345,12
Address
University Road Lanyon Building
BT7 1NN Belfast
Activity type
Higher or Secondary Education Establishments
WAGENINGEN UNIVERSITY
Netherlands
EU contribution
€ 265 619,88
Address
Droevendaalsesteeg 4
6708 PB Wageningen
Activity type
Higher or Secondary Education Establishments
TECHNISCHE UNIVERSITAET MUENCHEN
Germany
EU contribution
€ 252 788,40
Address
Arcisstrasse 21
80333 Muenchen
Activity type
Higher or Secondary Education Establishments
HEIDELBERG PHARMA RESEARCH GMBH
Germany
EU contribution
€ 252 788,40
Address
Schriesheimer Strasse 101
68526 Ladenburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ALMAC DISCOVERY LTD
United Kingdom
EU contribution
€ 303 172,56
Address
Almac House, 20 Seagoe Industrial Estate
BT63 5QD Craigavon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
SPIROCHEM AG
Switzerland
EU contribution
€ 281 276,64
Address
Mattenstrasse 24
4058 Basel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)